In November 1935 at Lisbon’s Santa Marta Hospital, Portuguese neurologist António Egas Moniz drilled into the skulls of his first twenty psychiatric patients, severing the white-matter tracts of the frontal lobes, and reported — on the basis of a few weeks of observation and no controls — that he had cured or improved most of them; the gap between that claim and the documented reality is the entire case. The reality was a procedure that, in its American form, lobotomized roughly 40,000 to 50,000 people, blunted or destroyed the personalities of a large fraction of them, killed on the order of one in twenty, and was performed most heavily on women, the institutionalized, children, and the powerless who could not consent. It was not validated against a sham, not measured against an inert comparator, not followed over the years it would have taken to see what it did; it was launched on the authority of a respected clinician working fast in a field that had nothing else to offer overcrowded asylums.
The operation did not fail quietly in a backwater. It was crowned. Moniz received the 1949 Nobel Prize in Physiology or Medicine “for his discovery of the therapeutic value of leucotomy in certain psychoses,” the only Nobel ever awarded for a surgical destruction of healthy brain tissue. That prize functioned as a regulatory and reputational green light: it converted an undertested operation into a respectable standard of care and supercharged its American evangelist, neurologist Walter Jackson Freeman II, who by the late 1960s had performed or supervised more than 3,500 lobotomies — a death toll among his own patients estimated at roughly 490.
Freeman’s signature innovation was to remove the operating room entirely. His “transorbital” or “ice-pick” lobotomy, first performed on a living patient on January 17, 1946, drove a leucotome through the thin bone of the eye socket and swept it across the frontal lobes, often in under ten minutes, frequently with no surgeon present and no general anaesthetic — he stunned patients with electroshock instead. He performed it on minors, on patients with headaches and depression, and on Rosemary Kennedy in 1941, who was left permanently incapacitated. The surrogate endpoint — a calmer, more “manageable” ward patient — was achieved. The actual endpoint — a recovered human being — usually was not.
The reckoning came not from a tribunal but from a molecule. Chlorpromazine, synthesized in 1950 and shown to control psychosis by 1952, offered the same institutional benefit — quieter, more tractable patients — without drilling through the skull. Within roughly a decade the lobotomy collapsed from a Nobel-honored frontier therapy to a byword for medical hubris. It was never recalled, never banned by a single statute; it was simply abandoned, made obsolete by a pill, and is now the textbook case of how prestige, a flattering surrogate measure, and an absence of controlled evidence can scale a mutilating procedure to tens of thousands before anyone is required to prove it works.
In 1987 a team led by neurologist Olle Lindvall and neuroscientist Anders Björklund at Lund University, Sweden, began implanting dopamine-producing cells dissected from aborted human fetuses into the brains of Parkinson’s patients; the open-label results of the 1990s — surviving grafts on PET, patients walking who had been frozen — were celebrated as the first biological cure for a neurodegenerative disease. The gap between that promise and the controlled evidence is the case. Tested the way a drug would be — against sham brain surgery, double-blind — the graft did not beat placebo on its primary endpoint and inflicted a new, largely untreatable harm: persistent involuntary movements that ran on after every drop of levodopa was withdrawn.
Both trials that ended the era were funded by the U.S. National Institutes of Health and built around a placebo arm earlier enthusiasts had called unnecessary. In Curt Freed’s Denver–Columbia trial, published in The New England Journal of Medicine on March 8, 2001, 40 patients aged 34 to 75 were randomized to a fetal-tissue graft or to sham surgery — burr holes drilled, no cells implanted. The graft showed no benefit on the pre-specified global rating; a positive signal appeared only in a post-hoc subgroup aged 60 or younger. Then came the harm: dystonia and dyskinesias in roughly 15 percent of grafted patients (5 of 33), persisting after levodopa was reduced or stopped. The second NIH trial, run by neurologist C. Warren Olanow and published in Annals of Neurology in September 2003, deepened the failure: across 34 patients, no significant effect on the motor UPDRS (p = 0.244) at 24 months, 56 percent with off-medication dyskinesia, and a conclusion that transplantation “currently cannot be recommended as a therapy.”
The case is exemplary because the grafts worked biologically and failed clinically. Fluorodopa uptake rose; dopamine neurons survived robustly and were confirmed at autopsy. The cells lived — but thriving grafts drove a runaway, unregulated release of dopamine the brain could not modulate, leaving a procedure that could not be titrated, withdrawn, or reversed: a worse failure mode than the disease it meant to cure. The field abandoned routine fetal grafting and turned to the problem it had skipped — proving, against placebo, that putting cells in a brain helps the person attached to it.
On October 30, 1967, in Zurich, the neurosurgeon M. Gazi Yaşargil sutured a scalp artery to a cortical branch of the middle cerebral artery under the operating microscope, rerouting blood around a blocked vessel to feed a starving brain; the operation was elegant, technically dazzling, and — for the prevention of stroke in patients with carotid and middle-cerebral disease — almost entirely unproven, and that gap between surgical beauty and clinical benefit is the entire case. For nearly two decades the extracranial-intracranial (EC-IC) arterial bypass spread on the strength of its own plausibility and on case series reporting open grafts, until a single randomized trial showed it prevented nothing it claimed to prevent.
The operation was never a fraud and never a mass killer in the lobotomy sense. It killed and disabled quietly, at the margins: a procedure with a roughly 12 percent thirty-day rate of stroke or death imposed up front on patients who, the trial would show, were no better protected afterward. The surrogate that sustained it was graft patency — the bypass stayed open in about 96 percent of cases, a number surgeons and angiograms could see and celebrate. A patent vessel looked like a prevented stroke. It was not the same thing, and conflating the two is the mechanism that kept the operation alive.
The reckoning arrived not from a regulator or a court but from an eight-year, NIH-funded randomized controlled trial led by the Canadian neurologist Henry J. M. Barnett of London, Ontario. Published in the New England Journal of Medicine on November 7, 1985, the International EC/IC Bypass Study randomized 1,377 patients at 71 centers in 14 countries and found that surgery added to best medical care did not reduce fatal or nonfatal stroke; two subgroups — patients with severe middle-cerebral stenosis and those with persisting symptoms after carotid occlusion — actually fared worse with the operation. Within a few years the procedure collapsed from a flourishing subspecialty to a narrow, rarely-indicated salvage technique. It was not banned. It was disconfirmed, and it became one of medicine’s foundational lessons in why a trial must precede an operation, not follow it.